Dendreon: How A Digital Manufacturing Solution Embeds Quality Into Cellular Therapeutics Production

Manufacturing personalized cellular therapies requires flawless execution under exceptionally tight timelines. For autologous treatments, where a single patient represents a distinct production batch, traditional paper-based record-keeping introduces significant latency and increases the risk of documentation errors. Transitioning to a digital manufacturing execution system eliminates specialized paper from sterile cleanrooms while embedding real-time quality controls directly into production workflows.

By adopting electronic batch records and review-by-exception functionality, cross-functional operations can pinpoint deviation risks immediately, coordinate cross-facility data, and accelerate batch release cycles. This modern approach ensures high-mix, personalized therapeutics move from apheresis to infusion without compromising data integrity or patient timelines.

Read this case study to explore how an advanced digital manufacturing solution helped a biopharmaceutical pioneer cut batch review and closure times by nearly 50% while maintaining a 99% right-first-time metric.